广州中医药大学临床药理研究所宓穗卿(Mi-SQ)论文被美国...

附件：

广州中医药大学临床药理研究所宓穗卿（Mi-SQ）论文被美国《科学

引文索引》SCI光盘版(2007年)收录情况

SCI CDE with Abstracts (Jan 07 - Dec 07) (D4.0)

Record 1 of 1.

Authors: Liu-CH Zhang-R Hong-X Huang-TL Mi-SQ Wang-NS

Title: PHARMACOKINETICS OF PIPERAQUINE AFTER SINGLE AND MULTIPLE ORAL ADMINISTRATIONS IN HEALTHY-VOLUNTEERS

Full source: YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 2007, Vol 127, Iss 10, pp 1709-1714

Language: English

Document type: Article

IDS/Book No.: 229FY

No. Related Records: 19

No. cited references: 11

Addresses: GUANGZHOU-UNIV-CHINESE-MED, INST CLIN PHARMACOL, GUANGZHOU 510405, GUANGDONG, PEOPLES-R-CHINA

Author keywords: HPLC-UV; PHARMACOKINETICS; PIPERAQUINE

KeyWords Plus: MALARIA; PREVENTION

Abstract: The aim of this work was to study the pharmaco kinetics of piperaquine in healthy volunteers. Healthy volunteers received piperaquine and tablets of Artekin by oral administration. The plasma samples were analyzed for piperaquine by liquid-liquid extraction and determined by HPLC-UV. The results demonstrated that the plasma drug concentration-time curves of single and multiple dose of piperaquine were fitted to a two-compartment open model. The pharmacokinetics parameters of piperaquine alone in a single dose were: t(1/2(beta)) (317.2-/+126.6)h, AUC(0 ->infinity)=(44293-/+ 12636)hXng/ml, V-d=(9490.9-/+2161.9)ml/kg, and Cl=(22.83-/+9.83)ml/h/kg. In Artekin in a single dose these parameters were: t(1/2(beta)) (302.8-/+180.7)h, AUC(0 ->infinity) = (46419-/+13670)hXng/ml, V-d=(10188.6-/+ 3520.3)ml/kg, and Cl= (25.48-/+10.89)ml/h/kg, while in Artekin in multiple doses they were: t(1/2(beta))= (298.9-/+ 101.9)h,AUC(0 ->infinity-)= (227692-/+56294)hxng/ml,V-d=(5031.5-/+1097.8)ml/kg, Cl=(11.91-/+3.046)ml/h/kg, respectively. The absorption and distribution of piperaquine were quick while the elimination was quite slow. There were significant differences in the pharmacokinetics parameters of piperaquine in Artekin between a single dose and multiple doses (p < 0.001), suggesting that piperaquine might accumulate in vivo and that attention should be given to its possible adverse drug reactions in clinical treatment.

Cited references:

CHEN-L-1982-CHIN-MED-J-V95-P281

CHEN-Q-1979-PHARM-IND-V8-P19

DENG-M-2004-CHINESE-J-CLIN-PHARM-V20-P67

HUNG-TY-2004-BRIT-J-CLIN-PHARMACO-V57-P253

RAYNES-K-1996-BIOCHEM-PHARMACOL-V52-P551

ROSHAMMAR-D-2006-EUR-J-CLIN-PHARMACOL-V62-P335 SUNDERLAND-B-2002-M-ANT-DRUG-DEV-SHANG-P41 VENNERSTROM-JL-1992-J-MED-CHEM-V35-P2129

WHITE-NJ-1996-PARASITOL-TODAY-V12-P399

WHITE-NJ-1999-PARASSITOLOGIA-V41-P310

ZUCKER-JR-1993-INFECT-DIS-CLIN-N-AM-V7-P547